The Food and Drug Administration has expanded its approval of Zytiga, the Johnson & Johnson prostate cancer pill. The pill was previously approved for those in earlier stages and is now approved for those in later stages (December 10).
The drug (abiraterone acetate), which increases the body's production of testosterone, may now be used to treat late-stage castration-resistant prostate cancer before the administration of chemotherapy.
The drug was initially approved in 2011 for men with prostate cancer who've taken the chemo drug, docetaxel. The latest approval comes on the heels of a Johnson & Johnson study of over one thousand men with late-stage prostate cancer. In the study, the average patient taking Zytiga outlasted his placebo taking counterpart by five months.
"Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer," the researchers wrote in the study.
by RTT Staff Writer
For comments and feedback: email@example.com